Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Jan 1;2(1):e22837.

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.

Author information

  • 1Department of Immunology; University of Connecticut Health Center; Farmington, CT USA.

Abstract

The ability of T cells to recognize a vast array of antigens enables them to destroy tumor cells while inflicting minimal collateral damage. Nevertheless, tumor antigens often are a form of self-antigen, and thus tumor immunity can be dampened by tolerance mechanisms that evolved to prevent autoimmunity. Since tolerance can be induced by steady-state antigen-presenting cells that provide insufficient co-stimulation, the exogenous administration of co-stimulatory agonists can favor the expansion and tumoricidal functions of tumor-specific T cells. Agonists of the co-stimulatory tumor necrosis factor receptor (TNFR) family members CD134 and CD137 exert antitumor activity in mice, and as monotherapies have exhibited encouraging results in clinical trials. This review focuses on how the dual administration of CD134 and CD137 agonists synergistically boosts T-cell priming and elaborates a multi-pronged antitumor immune response, as well as how such dual co-stimulation might be translated into effective anticancer therapies.

KEYWORDS:

CD134; CD137; CD4 T cell; dual costimulation; immunotherapy

PMID:
23482891
[PubMed]
PMCID:
PMC3583935
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Write to the Help Desk